Kintayl Capital LP Increases Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Kintayl Capital LP grew its position in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 96.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 99,973 shares of the biotechnology company's stock after purchasing an additional 48,979 shares during the period. Viking Therapeutics makes up 1.7% of Kintayl Capital LP's holdings, making the stock its 22nd largest position. Kintayl Capital LP owned approximately 0.09% of Viking Therapeutics worth $2,414,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Virtu Financial LLC acquired a new position in shares of Viking Therapeutics in the fourth quarter valued at about $1,715,000. Cambridge Investment Research Advisors Inc. increased its holdings in shares of Viking Therapeutics by 121.5% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 29,721 shares of the biotechnology company's stock valued at $718,000 after purchasing an additional 16,302 shares during the period. GAMMA Investing LLC increased its holdings in shares of Viking Therapeutics by 9,209.9% in the first quarter. GAMMA Investing LLC now owns 24,392 shares of the biotechnology company's stock valued at $589,000 after purchasing an additional 24,130 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Viking Therapeutics in the fourth quarter worth about $429,000. Finally, LPL Financial LLC boosted its stake in shares of Viking Therapeutics by 18.2% in the fourth quarter. LPL Financial LLC now owns 96,702 shares of the biotechnology company's stock worth $3,891,000 after buying an additional 14,873 shares during the last quarter. 76.03% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, COO Marianna Mancini sold 4,266 shares of the business's stock in a transaction on Thursday, July 3rd. The stock was sold at an average price of $27.77, for a total transaction of $118,466.82. Following the completion of the transaction, the chief operating officer directly owned 377,535 shares of the company's stock, valued at $10,484,146.95. The trade was a 1.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Brian Lian sold 26,889 shares of the business's stock in a transaction on Thursday, July 3rd. The stock was sold at an average price of $27.80, for a total value of $747,514.20. Following the transaction, the chief executive officer directly owned 2,388,014 shares of the company's stock, valued at $66,386,789.20. The trade was a 1.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 35,421 shares of company stock valued at $984,405 in the last three months. 4.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. The Goldman Sachs Group assumed coverage on Viking Therapeutics in a research note on Tuesday, April 8th. They issued a "neutral" rating and a $30.00 target price on the stock. Cantor Fitzgerald upgraded Viking Therapeutics to a "strong-buy" rating in a research note on Tuesday, April 29th. Morgan Stanley lowered their target price on Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. Truist Financial reiterated a "buy" rating and set a $75.00 price target (down previously from $95.00) on shares of Viking Therapeutics in a research report on Monday, April 28th. Finally, HC Wainwright restated a "buy" rating and issued a $102.00 target price on shares of Viking Therapeutics in a research report on Wednesday, June 25th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Viking Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $87.15.

Viking Therapeutics Stock Performance

Shares of NASDAQ VKTX traded up $0.37 during trading on Friday, reaching $32.44. The stock had a trading volume of 1,587,177 shares, compared to its average volume of 4,045,388. Viking Therapeutics, Inc. has a fifty-two week low of $18.92 and a fifty-two week high of $81.73. The business's 50-day moving average price is $27.90 and its 200-day moving average price is $29.11. The company has a market cap of $3.64 billion, a P/E ratio of -28.21 and a beta of 0.62.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.10). During the same quarter last year, the business earned ($0.26) earnings per share. The firm's revenue was up .0% compared to the same quarter last year. Analysts forecast that Viking Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.